ImmTAC/Anti‐PD‐1 antibody combination to enhance killing of cancer cells by reversing regulatory T‐cell‐mediated immunosuppression

Recently, bi‐functional molecules that can redirect immune effectors to tumour cells have emerged as potentially robust mediators of tumour regression in clinical trials. Two modalities in particular, bi‐specific antibodies for T‐cell redirection and activation (BiTe) and immune‐mobilizing monoclona...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Immunology
Main Authors: Zhang, Huanling, Li, Yanyan, Liu, Xiaoping, Liang, Zhaoduan, Yan, Mengyong, Liu, Qiang, Chen, Anan, Bao, Yifeng, Zhou, Chengzhi, Li, Shiyue, Yee, Cassian, Li, Yi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6142295/
https://ncbi.nlm.nih.gov/pubmed/29791021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imm.12954
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados